Literature DB >> 18419424

Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.

Carl Urban1, Patricia A Bradford, Margareta Tuckman, Sorana Segal-Maurer, Wehbeh Wehbeh, Louise Grenner, Rita Colon-Urban, Noriel Mariano, James J Rahal.   

Abstract

Nine carbapenem-resistant Escherichia coli isolates harboring Klebsiella pneumoniae carbapenemase (KPC)-2 or KPC-3 enzymes were identified in patients residing in 7 distinct long-term care facilities. Cefotaxime-hydrolyzing (CTX-M)-type beta-lactamases were also documented in 3 isolates. The identification of these enzymes in patients staying in long-term care facilities should be of great concern to all components of health care systems.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18419424     DOI： 10.1086/588048

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  30 in total

1.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity.

Authors:  David Landman; Carl Urban; Martin Bäcker; Paul Kelly; Neha Shah; Elizabeth Babu; Simona Bratu; John Quale
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

3.  In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models.

Authors:  Noe Reyes; James B Aggen; Corwin F Kostrub
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Carbapenem resistance in Canada.

Authors:  Baldwin Toye; Sigmund Krajden; Milan Fuksa; Donald E Low; Dylan R Pillai
Journal:  CMAJ       Date:  2009-06-09       Impact factor: 8.262

5.  Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli.

Authors:  Jennifer M Adams-Haduch; Brian A Potoski; Hanna E Sidjabat; David L Paterson; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

6.  Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients.

Authors:  Joanna Kopacz; Noriel Mariano; Rita Colon-Urban; Paul Sychangco; Wehbeh Wehbeh; Sorana Segal-Maurer; Carl Urban
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

7.  Polymyxin-resistant clinical isolates of Escherichia coli.

Authors:  Carl Urban; Hemavarna Tiruvury; Noriel Mariano; Rita Colon-Urban; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

8.  Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China.

Authors:  Jia Chang Cai; Rong Zhang; Yan Yan Hu; Hong Wei Zhou; Gong-Xiang Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.

Authors:  Mao Hagihara; Jared L Crandon; Carl M Urban; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.